Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

3 Humongous Health-Care Stocks This Week
Motley Fool
Saturday, January 12, 2013 - 10:47am
tags:
Isis Pharmaceuticals, Celgene, Dynavax Technologies
3 Biotech Growth Stocks Near Highs
Seeking Alpha
Saturday, January 12, 2013 - 10:45am
tags:
Celgene, Valiant, Regeneron
Trader thinks Jazz may hit sour note
Yahoo/Option Monster
Saturday, January 12, 2013 - 10:45am
tags:
Jazz Pharmaceuticals
Which Companies Are In Michael King's Oncology Wheelhouse?
Seeking Alpha
Saturday, January 12, 2013 - 10:44am
tags:
Alnylam, Regulus, Isis Pharmaceuticals, SynaGeva BioPharma, Sarepta Therapeutics, Onyx, Celgene, Millennium, Takeda, Ariad Pharmaceuticals, Pharmacyclics, Astex
The Soft Underbelly of Ziopharm Oncology
Motley Fool
Saturday, January 12, 2013 - 10:39am
tags:
Ziopharm
3 Horrendous Health-Care Stocks This Week
Motley Fool
Saturday, January 12, 2013 - 10:38am
tags:
Arqule, Sequenom, Idenix
BGI-Shenzhen Extends Tender Offer for Complete Genomics, Inc.
Yahoo/PR Newswire
Saturday, January 12, 2013 - 10:38am
tags:
BGI-Shenzhen, Complete Genomics, M&A
1 Problem This Pharma Doesn’t Want to Talk About
Motley Fool
Saturday, January 12, 2013 - 10:36am
tags:
Copaxone, Teva Pharmaceuticals, multiple sclerosis, MS, patents
1 Problem This Pharma Doesn’t Want to Talk About
Motley Fool
Saturday, January 12, 2013 - 10:36am
tags:
Copaxone, Teva Pharmaceuticals, multiple sclerosis, MS
Will Sarepta Be Bought Out in 2013?
Motley Fool
Saturday, January 12, 2013 - 10:34am
tags:
Sarepta Therapeutics
Alexion Pharmaceuticals Inc.: Today's Featured Drugs Laggard
The Street
Saturday, January 12, 2013 - 10:34am
tags:
Alexion
Banking on Biotech
CNBC
Saturday, January 12, 2013 - 10:33am
tags:
Regeneron, Biogen Idec, Acorda Therapeutics, Sanofi, Celgene, Alexion, Biomarin, NPS Pharmaceuticals, Cerner, EXACT Sciences, Pfizer, Bristol-Myers Squibb, Eli Lilly
Sarepta May Seek Partnership Advice for Experimental Drug
Bloomberg
Saturday, January 12, 2013 - 10:29am
tags:
Sarepta Therapeutics, eteplirsen, Duchenne Muscular Dystrophy
Humira Will Help AbbVie Prevail, A Great Buy With Low Valuation
Seeking Alpha
Friday, January 11, 2013 - 12:43pm
tags:
Humira, AbbVie, Abbott Laboratories
Celsion's Phase III Blockbuster Data Revealed And It's Been Right Underneath Your Nose
Seeking Alpha
Friday, January 11, 2013 - 12:16pm
tags:
Celsion, ThermoDox
Will Qsymia's Stellar Sales Growth Continue?
Motley Fool
Friday, January 11, 2013 - 12:15pm
tags:
Vivus, Qsymia, obesity
10 Biotech Stocks With A History Of Beating Earning Expectations
TheStreet.com
Friday, January 11, 2013 - 12:14pm
tags:
Alexion, Regeneron, Optimer, Targacept, Osiris, Array Biopharma, YM BioSciences, Questcor Pharmaceuticals, Charles River Laboratories, Illumina
Sarepta May Seek Partnership Advice for Experimental Drug
Bloomberg
Friday, January 11, 2013 - 12:12pm
tags:
Sarepta, eteplirsen, Duchenne Muscular Dystrophy
Dendreon Rises on Optimism Over Cancer Drug Provenge
Bloomberg
Friday, January 11, 2013 - 12:05pm
tags:
Dendreon, prostate cancer, Provenge
Good Chance For PharmAthene To Jump On Lucrative SIGA Litigation
Seeking Alpha
Friday, January 11, 2013 - 12:05pm
tags:
PharmAthene, SIGA technologies

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.